Skip to main content

Table 1 DNBC-derived CEIs are associated with tumor response to neoadjuvant chemotherapy in DNBC cohorts

From: Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response

    

AUC

cohort

regimen

patients

responders

CEI1

CEI2

CEI3

CEI4

CEI5

CEI6

EORTC

FEC

37

16

0.73R*

0.57

0.51R

0.61

0.56

0.54

MDA1

TFAC

27

13

0.78 **

0.62

0.77**

0.61R

0.53

0.61

MDA/MAQC

TFAC

30

9

0.77*

0.66

0.78*

0.62R

0.58

0.54

DFCI2

P

24

4

0.73

0.72R

0.50

0.52R

0.52R

0.57R

JBI2

E

43

4

0.85R*

0.73R

0.53

0.88**

0.58R

0.72

  1. Each CEI was evaluated as a univariate predictor of pathological complete response or residual disease using the area under the ROC curve (AUC). Chemotherapy regimens are indicated: A, doxorubicin; C, cyclophosphamide; E, epirubicin; F, 5-fluorouracil; P, either cisplatin or carboplatin; T, either paclitaxel or docetaxel. The CEIs were derived from four independent DNBC cohorts not shown in this table. * P < 0.05; ** P < 0.01. R: AUC is estimated based on association to residual disease (RD).